Comparative Pharmacology
Head-to-head clinical analysis: ABSORICA LD versus TRETINOIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ABSORICA LD versus TRETINOIN.
ABSORICA LD vs TRETINOIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Retinoid that reduces sebum production, normalizes follicular keratinization, and inhibits Propionibacterium acnes growth via modulation of gene expression.
Retinoic acid receptor agonist; binds to RAR and RXR nuclear receptors, modulating gene transcription involved in cell differentiation, proliferation, and apoptosis.
0.5-1 mg/kg/day orally divided twice daily for 4-5 months, max 2 mg/kg/day.
Acute promyelocytic leukemia (APL): 45 mg/m2/day orally divided twice daily, as induction therapy.
None Documented
None Documented
Terminal elimination half-life is 21 hours (range 7–39 hours) for isotretinoin. Clinical context: Steady-state achieved after 5–7 days of dosing.
Clinical Note
moderateTretinoin + Digoxin
"Tretinoin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateAlitretinoin + Digoxin
"Alitretinoin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateTretinoin + Digitoxin
"Tretinoin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateAlitretinoin + Digitoxin
"Alitretinoin may decrease the cardiotoxic activities of Digitoxin."
Terminal elimination half-life is 0.5-2 hours for the parent drug, but may be prolonged to 10-12 hours after multiple dosing due to reduced clearance; clinical context: t1/2 is short, requiring frequent or continuous dosing to maintain therapeutic levels.
Primarily renal, 65% as unchanged drug; 35% as metabolites. Fecal elimination accounts for less than 5%.
Primarily fecal (approx. 60%) via biliary excretion as metabolites; renal excretion accounts for <15% of a dose as unchanged drug and metabolites.
Category C
Category D/X
Retinoid
Retinoid